Business
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in our aesthetics portfolio and insights on the aesthetic mindset of an emerging patient population.
About this update from Abbvie Inc.
[{"type":"text","content":"- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid onset and a consistently favorable safety profile across studied patient populations","length":198,"tagName":"p"},{"type":"text","content":"- Poster presentation explores mindset and characteristics of GLP-1 agonist-treated patients in aesthetic clinics","length":113,"tagName":"p"},{"type":"text","content":"NORTH CHICAGO, Ill., March 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in our aesthetics portfolio and insights on the aesthetic mindset of an emerging patient population.","length":335,"tagName":"p"},{"type":"text","content":""At Allergan Aesthetics, we are dedicated to scientific research that reinforces customer and patient trust and confidence in our broad product portfolio," said John Maltman, Ph.D., vice president, global aesthetics medical affairs, Allergan Aesthetics. "Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients' aesthetic concerns."","length":452,"tagName":"p"},{"type":"text","content":"Data from Safety and Efficacy of TrenibotulinumtoxinE Following Repeat Treatments for Glabellar Lines: Findings From an Open-Label Phase 3 Study report findings from an 18-week, open-label, Phase 3 study evaluating the safety and efficacy of repeat TrenibotE (up to 3 open-label treatments) for glabellar lines showed a consistent safety profile.","length":346,"tagName":"p"},{"type":"text","content":"TrenibotE is an investigational first-in-class botulinum neurotoxin serotype E characterized by rapid results, as early as 8 hours after administration (earliest assessment time), and shorter duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind available to patients.","length":326,"tagName":"p"},{"type":"text","content":"Key findings include: ","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TrenibotE was well-tolerated over 3 sequential open-label treatments, showing a consistent safety profile, no new safety concerns, and no neutralizing anti...